Cover Image
QR Code

Pharmacology notes. Doripenem (Doribax): the newest addition to the carbapenems.

Carbapenems are a class of antimicrobials structurally related to penicillin. Doripenem, the newest agent in this class, was recently approved by the Food and Drug Administration for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. Its spectrum of act...

Full description

Published in:Baylor University Medical Center Proceedings Vol. 21; no. 3; pp. 337 - 342
Main Author: Greer ND
Format: tables/charts Journal Article
Published: Taylor & Francis Ltd Jul2008
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105775237&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105775237
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        08998280
        1XEP
      jtl: Baylor University Medical Center Proceedings
      issn: 08998280
      maglogo: N
    pubinfo:
      dt: Jul2008
      vid: 21
      iid: 3
      pid: 377
      pub: Taylor & Francis Ltd
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        105775237
        105775237
        2009965717
        10.1080/08998280.2008.11928422
        NLM18628935
        105775237
      ppf: 337
      ppct: 5
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Pharmacology notes. Doripenem (Doribax): the newest addition to the carbapenems.
      aug:
        au: Greer ND
        affil: Department of Pharmacy Services, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246; NickiG@BaylorHealth.edu
      sug:
        subj:
          Carbapenems Analogs and Derivatives
          Pharmacy and Pharmacology
          Carbapenems Administration and Dosage
          Carbapenems Adverse Effects
          Carbapenems Pharmacodynamics
          Carbapenems Pharmacokinetics
          Carbapenems Therapeutic Use
          Clinical Trials
          Drug Interactions
          Drug Resistance, Microbial
          United States Food and Drug Administration
          Urinary Tract Infections Drug Therapy
      ab: Carbapenems are a class of antimicrobials structurally related to penicillin. Doripenem, the newest agent in this class, was recently approved by the Food and Drug Administration for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. Its spectrum of activity is similar to that of meropenem and imipenem/cilastatin. Some studies indicate that approximately 29% of carbapenem-resistant Pseudomonas aeruginosa isolates may remain sensitive to doripenem, although the clinical relevance of that finding has not been determined. Clinical studies, which have been published only in abstract form to date, have found doripenem to be similar to comparator agents. The most common adverse effects related to doripenem therapy were headache, nausea, diarrhea, rash, and phlebitis. Doripenem, like the other carbapenems, may also cause seizures. Because of the lack of published data, the lack of clear advantages over meropenem, and the increased cost compared with meropenem, doripenem will not be available for use at Baylor University Medical Center except by infectious diseases specialists.
      pubtype: Academic Journal
      doctype:
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N